Targeting survivin as a potential new treatment for chondrosarcoma of bone
Open Access
- 9 May 2016
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 5 (5) , e222
Abstract
Chondrosarcomas are malignant cartilage-forming bone tumors, which are intrinsically resistant to chemo- and radiotherapy, leaving surgical removal as the only curative treatment option. Therefore, our aim was to identify genes involved in chondrosarcoma cell survival that could serve as a target for therapy. siRNA screening for 51 apoptosis-related genes in JJ012 chondrosarcoma cells identified BIRC5, encoding survivin, as essential for chondrosarcoma survival. Using immunohistochemistry, nuclear as well as cytoplasmic survivin expression was analyzed in 207 chondrosarcomas of different subtypes. Nuclear survivin has been implicated in cell-cycle regulation while cytoplasmic localization is important for its anti-apoptotic function. RT–PCR was performed to determine expression of the most common survivin isoforms. Sensitivity to YM155, a survivin inhibitor currently in phase I/II clinical trial for other tumors, was examined in 10 chondrosarcoma cell lines using viability assay, apoptosis assay and cell-cycle analysis. Survivin expression was found in all chondrosarcoma patient samples. Higher expression of nuclear and cytoplasmic survivin was observed with increasing histological grade in central chondrosarcomas. Inhibition of survivin using YM155 showed that especially TP53 mutant cell lines were sensitive, but no caspase 3/7 or PARP cleavage was observed. Rather, YM155 treatment resulted in a block in S phase in two out of three chondrosarcoma cell lines, indicating that survivin is more involved in cell-cycle regulation than in apoptosis. Thus, survivin is important for chondrosarcoma survival and chondrosarcoma patients might benefit from survivin inhibition using YM155, for which TP53 mutational status can serve as a predictive biomarker.Keywords
This publication has 46 references indexed in Scilit:
- Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancersDrug Discovery Today, 2015
- Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcomaThe Journal of Pathology, 2015
- Survivin – The inconvenient IAPSeminars in Cell & Developmental Biology, 2015
- SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathwayMedical Oncology, 2014
- Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of boneBMC Cancer, 2012
- Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.2012
- Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for TreatmentCancer Research, 2009
- Survivin, cancer networks and pathway-directed drug discoveryNature Reviews Cancer, 2008
- YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor XenograftsCancer Research, 2007
- Survivin, a cancer target with an emerging role in normal adult tissuesMolecular Cancer Therapeutics, 2006